The First-in-Class SIK3 Inhibitor O3R-5671 Demonstrates Optimal Pharmacokinetics and Potent and Sustained Pharmacodynamic Activity in Human Participants

PK/PD correlation data indicates that doses of 15 mg of O3R-5671 and above lead to maximum TNFa inhibition in the range of that achieved with biologics. Concentrations maximally inhibiting TNFa correlate with SIK3 EC80 and do not inhibit SIK2. O3R-5671 is safe and well tolerated and dose escalation continues in the study.